StrideBio, Inc is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies and therapeutics for rare diseases. Our STRucture Inspired DEsign approach holds the potential to generate unique AAV capsids capable of overcoming the challenges of pre-existing neutralizing antibodies and improving gene transfer efficiency in patients. This powerful new approach has broad application, enabling gene addition, gene silencing and gene editing modalities for a wide range of diseases, including rare genetic diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/13/18 | $15,700,000 | Series A |
Alexandria Real Estate Equities Hatteras Venture Partners  Takeda Ventures UCB | undisclosed |
| 03/16/21 | $81,500,000 | Series B |
Alexandria Venture Investments CaaS Capital Management Hatteras Venture Partners Northpond Ventures Novo Holdings Octagon Capital Pontifax Sarepta Therapeutics Takeda Ventures UCB Ventures UF Innovate Ventures | undisclosed |
